ライフサイエンスコーパス: FDG

1 FDG-PET detected plaque inflammation in 12/13 patients s

2 ere Abeta-N+ (24.9%; 30 FDG+, 33 HV+, and 11 FDG+HV+) and 37 were Abeta+N+ (17.7%; 22 FDG+, 26 HV+, a

3 ere Abeta+N+ (17.7%; 22 FDG+, 26 HV+, and 11 FDG+HV+).

4 8 FDG+HV+) and 187 were Abeta+N+ (39.9%; 135 FDG+, 147 HV+, and 95 FDG+HV+ cases).

5 Therefore, using (18)FDG and microPET, we measured differences in regional br

6 11 FDG+HV+) and 37 were Abeta+N+ (17.7%; 22 FDG+, 26 HV+, and 11 FDG+HV+).

7 rkers; of these, 52 were Abeta-N+ (24.9%; 30 FDG+, 33 HV+, and 11 FDG+HV+) and 37 were Abeta+N+ (17.7

8 ere Abeta-N+ (22.8%; 63 FDG+, 82 HV+, and 38 FDG+HV+) and 187 were Abeta+N+ (39.9%; 135 FDG+, 147 HV+

9 these patients, 107 were Abeta-N+ (22.8%; 63 FDG+, 82 HV+, and 38 FDG+HV+) and 187 were Abeta+N+ (39.

10 e Abeta+N+ (39.9%; 135 FDG+, 147 HV+, and 95 FDG+HV+ cases).

11 features extracted from Dixon sequences and FDG PET.

12 ion with high relative metabolic activity at FDG PET had a shorter survival time than did those with

13 e relationship between metabolic activity at FDG PET in the residual lesion identified at brain MR im

14 val time than did those with low activity at FDG PET.

15 d investigate voxelwise correlations between FDG metabolism and cognitive score at baseline.

16 tabolically active bone marrow documented by FDG uptake and with the number of RANKL + cells present

17 Baseline parietal to cerebellum FDG metabolism ratios predicted MMSE (beta=0.38, p=0.001

18 Conclusion FDG PET/CT demonstrates high specificity and PPV for det

19 Conclusion FDG PET/CT has satisfactory diagnostic accuracy in the d

20 Conclusion FDG-PET/CT surveillance using Hopkins criteria 12 weeks

21 Reductions in cortical FDG metabolism were present in newly diagnosed PD, and c

22 was used to evaluate how levels of cortical FDG metabolism were predictive of subsequent cognitive d

23 s, especially by texture features on delayed FDG PET/CT images.

24 rease in uptake for both (18)F-FDS and (18)F-FDG (9.2 and 3.9).

25 sions and the pituitary gland; and for (18)F-FDG (C)-RD of SUVs of the whole brain and 10 anatomic re

26 and studies of healthy subjects using (18)F-FDG (n = 11).

27 ated in a cross-sectional design using (18)F-FDG (n = 43) and translocator protein (TSPO) ((18)F-GE18

28 soft-tissue or no metastasis for both (18)F-FDG (P = 0.037) and (68)Ga-DOTATATE (P = 0.047).

29 e feasibility of using CR generated by (18)F-FDG accumulated in tumors to induce photoimmunotherapy.

30 ommonly available radiopharmaceuticals-(18)F-FDG and (18)F-NaF-have been used in clinical research fo

31 Fibrosarcoma cells were incubated with (18)F-FDG and exposed to Cy7 azide with subsequent fluorescenc

32 rformed immediately after injection of (18)F-FDG around the tumor or intracutaneously in the contrala

33 ) deficiency are characterized by high (18)F-FDG avidity.

34 PET with (18)F-FDG captures neuronal activity that is in steady state a

35 There was a 30% deficit in (18)F-FDG concentration, which was restored by iMAR processing

36 ly simulated the stepwise reduction of (18)F-FDG doses of 19 patients (mean age +/- SD, 50.9 +/- 11.7

37 Positron lymphography using (18)F-FDG followed by Cerenkov-guided resection of lymph nodes

38 ramycin with the current gold standard (18)F-FDG for treatment response evaluation after targeted the

39 with PET/CT using either (18)F-FDS or (18)F-FDG from days 1 to 4 after inoculation.

40 interest determined using coregistered (18)F-FDG images for both the volume of interest-averaged and

41 In addition, (18)F-FDG images were obtained during the cold stress conditio

42 In this study, (89)Zr-transferrin and (18)F-FDG imaging were compared in preclinical models of TNBC.

43 ateness of antibiotic treatment before (18)F-FDG imaging were recorded.

44 es of infection are often referred for (18)F-FDG imaging while already receiving antibiotic treatment

45 Uptake of both (18)F-FDS and (18)F-FDG in infected lung could be used to track the degree o

46 alues of fetal dosimetry deriving from (18)F-FDG injection in pregnant women are estimated from anima

47 ins at 3 h (delayed examination) after (18)F-FDG injection.

48 PET/CT using (18)F-FDG is an essential part of the management of patients w

49 was visually scored 0 or 1 concerning (18)F-FDG LN uptake relative to background.

50 However, retention after (18)F-FDG lymphography was also seen in acute inflammatory lym

51 nguished from normal nodes via dynamic (18)F-FDG lymphography, to then be resected under Cerenkov ima

52 When applied to the dynamic (18)F-FDG measurement of colon cancer, the proposed algorithm

53 pare pharmacokinetic rate constants of (18)F-FDG metabolism, including regional variation, between NS

54 vs. 8 +/- 3 mm(2); n = 3 vs. 6), day-4 (18)F-FDG PET (metabolic volume, 87 +/- 23 vs. 118 +/- 14 mm(3

55 igher specificity (0.89 vs. 0.79) than (18)F-FDG PET alone, with no evidence of significant differenc

56 A prespecified (18)F-FDG PET analysis was conducted to assess the predictive

57 Conclusion:(18)F-FDG PET and MR ADC histogram metrics in pediatric DIPG d

58 Data about the significance of (18)F-FDG PET at interim assessment and end of treatment in pe

59 the use of analysis of covariance, all (18)F-FDG PET brain images of MMF patients were compared with

60 Methods:(18)F-FDG PET brain imaging and a comprehensive battery of neu

61 (18)F-FDG PET data from patients with refractory or advanced d

62 nted independent-component analysis of (18)F-FDG PET data in 5 groups of subjects with cognitive stat

63 Independent-component analysis of (18)F-FDG PET data showed a gradual disruption of functional b

64 (18)F-FDG PET data were acquired along with 2 Dixon MR-AC maps

65 Performing (18)F-FDG PET for early evaluation of response often results i

66 d improve upon the current standard of (18)F-FDG PET for MYC-overexpressing TNBC.

67 aphy (PET) has added value over static (18)F-FDG PET for tumor delineation in non-small cell lung can

68 (18)F-FDG PET identified intense inter-scapular BAT glucose up

69 FLAB-based segmentation on static (18)F-FDG PET images is in best agreement with pathology volum

70 plored for biomarker development, with (18)F-FDG PET imaging being the most studied.

71 ssessed by (99m)Tc-duramycin SPECT and (18)F-FDG PET imaging in treatment-sensitive COLO205 and treat

72 (18)F-FDG PET imaging is routinely used to investigate brown a

73 estigate glucose utilization of BAT by (18)F-FDG PET imaging.

74 sed on early evaluation of response by (18)F-FDG PET in patients in the Dutch GIST registry treated w

75 asibility of quantitative small-animal (18)F-FDG PET in rats by performing it repeatedly to monitor t

76 essed by serial CT tumor volumetry and (18)F-FDG PET metabolic volume.

77 (18)F-FDG PET often exhibits nonspecific internalization and l

78 e diagnostic performance of whole-body (18)F-FDG PET or (18)F-FDG PET/CT for detection of underlying

79 cificity, and diagnostic odds ratio of (18)F-FDG PET or (18)F-FDG PET/CT for the detection of underly

80 e studies demonstrates that whole-body (18)F-FDG PET or (18)F-FDG PET/CT has high diagnostic accuracy

81 d studies reporting the performance of (18)F-FDG PET or (18)F-FDG PET/CT in patients with suspected p

82 is article reviews the data evaluating (18)F-FDG PET quantification approaches in lung diseases, focu

83 the reproducibility of their impact on (18)F-FDG PET quantification in patients with non-small cell l

84 We confirmed that (18)F-FDG PET scanning is a reliable tool for BMI assessment i

85 Seventy (18)F-FDG PET scans were obtained for 63 GIST patients to eval

86 Next, we discuss how (18)F-FDG PET studies have advanced understanding of the relat

87 In addition, the value of (18)F-FDG PET studies in differential diagnosis, identifying p

88 This review focuses on recent human (18)F-FDG PET studies in Parkinson disease.

89 We performed longitudinal (18)F-FDG PET studies on 9 different PDX groups obtained by im

90 d to simulate clinical and preclinical (18)F-FDG PET time-activity curves using population-based arte

91 discordance affects the capability of (18)F-FDG PET to stratify lymphoma patients.

92 of this study was to describe baseline (18)F-FDG PET voxel characteristics in pediatric diffuse intri

93 ative brain metabolism using pediatric (18)F-FDG PET with CT data of normal pediatric brains, account

94 lytic flux seen in inflammatory cells ((18)F-FDG PET).

95 ompared with positive end-of-treatment (18)F-FDG PET, negative scans, indicating a CMR, were predicti

96 with occipital lobe hypometabolism on (18)F-FDG PET, whereas relative sparing of posterior cingulate

97 A total of 13 articles (11 studies for (18)F-FDG PET-CT and 2 for LS), met the inclusion criteria.

98 Both (18)F-FDG PET-CT and LS yield high sensitivity, specificity, a

99 ED infection, based on robust data for (18)F-FDG PET-CT but limited data for LS.

100 The pooled sensitivity of (18)F-FDG PET-CT for the diagnosis of CIED infection was 87% (

101 When available,(18)F-FDG PET-CT may be preferred.

102 tologic type and clinical T stage, the (18)F-FDG PET-derived textural feature long run low gray level

103 and 13 probable DLB subjects underwent (18)F-FDG PET.

104 oscopy of hyperpolarized pyruvate, and (18)F-FDG PET/computed tomographic (CT) imaging were performed

105 Conclusion:(18)F-FDG PET/CT after 1 treatment cycle is predictive of outc

106 discordant metabolic activity by both (18)F-FDG PET/CT and (11)C-MET PET/CT were Waldeyer's ring, pa

107 Clinical data and results of (18)F-FDG PET/CT and other imaging techniques, including echoc

108 nts underwent systematic posttreatment (18)F-FDG PET/CT and were followed with at least a clinical ex

109 Clinical data and results from (18)F-FDG PET/CT at diagnosis and during follow-up were collec

110 (18)F-FDG PET/CT can be considered a valuable tool for the wor

111 (18)F-FDG PET/CT can be coupled with sensitive bone marrow-bas

112 (18)F-FDG PET/CT changed patient management in 14 cases (16%),

113 Conclusion:(18)F-FDG PET/CT correctly identified foci of increased uptake

114 IRT and (18)F-FDG PET/CT data from 8 healthy men subjected to water-ja

115 pazopanib in ovarian cancer even when (18)F-FDG PET/CT does not indicate a response.

116 Seventy-one (18)F-FDG PET/CT examinations were performed for 32 patients.

117 The (68)Ga-DOTATATE and (18)F-FDG PET/CT findings were discordant in 65 patients (62.5

118 ), had normal MRI results and abnormal (18)F-FDG PET/CT findings whereas the other subsets demonstrat

119 5.2% and 77.8% on standard and delayed (18)F-FDG PET/CT for an SUVmax cutoff of greater than 1.32 and

120 , we recruited all those who underwent (18)F-FDG PET/CT for clinical reasons at our institution befor

121 ormance of whole-body (18)F-FDG PET or (18)F-FDG PET/CT for detection of underlying malignancy in pat

122 gnostic odds ratio of (18)F-FDG PET or (18)F-FDG PET/CT for the detection of underlying malignancy we

123 purpose of this study was to evaluate (18)F-FDG PET/CT for the diagnosis, management, and treatment

124 osis in the CT group compared with the (18)F-FDG PET/CT group (11.6 vs. 5.7 d; P = 0.02).

125 (18)F-FDG PET/CT had no clinical impact on G1 NETs and a moder

126 rates that whole-body (18)F-FDG PET or (18)F-FDG PET/CT has high diagnostic accuracy and moderate to

127 The predominant finding on brain (18)F-FDG PET/CT imaging was lobar hypometabolism, being obser

128 bserved with the control group or with (18)F-FDG PET/CT imaging.

129 e investigated the diagnostic value of (18)F-FDG PET/CT in chronic Q fever at diagnosis and during fo

130 his study, we investigated the role of (18)F-FDG PET/CT in patients with SAB for detection of metasta

131 ng the performance of (18)F-FDG PET or (18)F-FDG PET/CT in patients with suspected paraneoplastic syn

132 dy of all adult patients who underwent (18)F-FDG PET/CT in search of a focal source of infection was

133 All patients underwent two (18)F-FDG PET/CT investigations on two different days (time di

134 Conclusion:(18)F-FDG PET/CT is a valuable technique for early detection o

135 Conclusion:(18)F-FDG PET/CT is a valuable technique in diagnosis of chron

136 The use of (18)F-FDG PET/CT is mandatory to confirm a suspected diagnosis

137 (18)F-FDG PET/CT is often used for restaging after NAC and to

138 (18)F-FDG PET/CT led to a total of 104 treatment modifications

139 ents were randomized 1:1 to whole-body (18)F-FDG PET/CT or CT of the thorax and abdomen as the imagin

140 hod for early response evaluation with (18)F-FDG PET/CT performed most optimally for the prediction o

141 high-risk bacteremia patients without (18)F-FDG PET/CT performed than in those in whom (18)F-FDG PET

142 owever, in poorly differentiated NETs, (18)F-FDG PET/CT plays a significant clinical role in combinat

143 Conclusion:(18)F-FDG PET/CT results may act as a biomarker for the presen

144 hy, white blood cell scintigraphy, and (18)F-FDG PET/CT results.

145 ts underwent a preoperative whole-body (18)F-FDG PET/CT scan at 1 h (standard examination) and an add

146 locally advanced EC and a pretreatment (18)F-FDG PET/CT scan between 2009 and 2015.

147 ed until March 2015, when at least one (18)F-FDG PET/CT scan was obtained.

148 Three-month (18)F-FDG PET/CT scans detected HL patients responding to anti

149 (18)F-FDG PET/CT scans of 14 patients with metal implants (eit

150 rvices coverage includes 3 posttherapy (18)F-FDG PET/CT scans per patient and per tumor type.

151 Of all (18)F-FDG PET/CT scans performed at diagnosis, 13.5% led to a

152 erall, fourth and subsequent follow-up (18)F-FDG PET/CT scans resulted in change in management in 31.

153 During follow-up, 57.3% of (18)F-FDG PET/CT scans resulted in treatment modification.

154 Methods:(18)F-FDG PET/CT scans were obtained before and after 7-10 d o

155 Any additional follow-up (18)F-FDG PET/CT scans will be reimbursed at the discretion of

156 All had paired (11)C-MET PET/CT and (18)F-FDG PET/CT studies at diagnosis.

157 he final study population included 176 (18)F-FDG PET/CT studies in 153 patients (107 men, 46 women; a

158 (18)F-FDG PET/CT studies were analyzed both qualitatively and

159 tive (29%) and 17 false-positive (10%) (18)F-FDG PET/CT studies.

160 Based on the ability of (18)F-FDG PET/CT to distinguish between metabolically active a

161 cephalitides, comparing the utility of (18)F-FDG PET/CT versus conventional brain imaging with MRI.

162 nd without vascular infection based on (18)F-FDG PET/CT was 23.8% and 2.1%, respectively (P = 0.001).

163 When (18)F-FDG PET/CT was added as a major criterion to the modifie

164 In a subgroup analysis, (18)F-FDG PET/CT was found to have a significantly higher spec

165 PET/CT performed than in those in whom (18)F-FDG PET/CT was performed (32.7% vs. 12.4%, P = 0.003).

166 (18)F-FDG PET/CT was performed 1-8 mo (median, 4 mo) after com

167 ients with advanced nonsquamous NSCLC, (18)F-FDG PET/CT was performed before treatment and after 2 wk

168 tal of 184 patients were included, and (18)F-FDG PET/CT was performed in 105 patients, of whom 99 had

169 atic complications were present before (18)F-FDG PET/CT was performed.

170 In multivariate analysis, (18)F-FDG PET/CT was the only factor independently associated

171 abolic tumor volume (TMTV) measured on (18)F-FDG PET/CT with adaptive thresholding methods with TMTV

172 nical examination, and who had initial (18)F-FDG PET/CT within 3 mo after pathologic breast cancer di

173 The following (18)F-FDG PET/CT-derived parameters were computed: maximum dia

174 he associations among CTCs, cfDNA, and (18)F-FDG PET/CT-derived parameters were evaluated by multivar

175 underwent complete staging, including (18)F-FDG PET/CT.

176 bility rate of infectious processes by (18)F-FDG PET/CT.

177 ution of (11)C-MET PET/CT with that of (18)F-FDG PET/CT.

178 tion was minimal in non-time-of-flight (18)F-FDG PET/MR brain imaging.

179 nts, a clinically indicated whole-body (18)F-FDG PET/MR scan was acquired.

180 technique was assessed in simultaneous (18)F-FDG PET/MR scans of a canine model of myocardial infarct

181 The feasibility of (18)F-FDG PET/MRI for diagnosing pain generators in chronic sc

182 Whole-body (18)F-FDG PET/MRI scans were obtained for 12 patients after PE

183 Methods:(18)F-FDG PET/MRI was performed on 9 chronic sciatica patients

184 nd on oncologic readings in whole-body (18)F-FDG PET/MRI.

185 Glucose metabolic rate, (18)F-FDG phosphorylation rate, and VB were less heterogeneous

186 agement decision was based on only the (18)F-FDG results.

187 ), without significance differences in (18)F-FDG SUVmax Log-rank analysis showed statistically signif

188 and low BAT) based on the presence of (18)F-FDG tracer uptake.

189 ependent predictor of (11)C-HED RI and (18)F-FDG uptake across thermoneutral and cold conditions.

190 (18)F-FDG uptake and diffusion were measured using SUV and app

191 No correlation between (18)F-FDG uptake and DWI could be found across patients, but w

192 ting in an overall correlation between (18)F-FDG uptake and TSPO binding (R = 0.69, P < 0.005).

193 umans, active BAT can be visualized by (18)F-FDG uptake as detected by PET combined with CT.

194 n of succinate significantly increased (18)F-FDG uptake at 24 h on small-animal PET/CT imaging and au

195 hese results imply that low myocardial (18)F-FDG uptake before the initiation of doxorubicin chemothe

196 found that succinate caused increased (18)F-FDG uptake by human umbilical vein endothelial cells in

197 mistry was performed to assess whether (18)F-FDG uptake correlates with GLUT1 staining.

198 Results:(18)F-FDG uptake identified subjects with high and low levels

199 different patterns of bone marrow (BM) (18)F-FDG uptake in HL.

200 alysis using SUVmax was performed, and (18)F-FDG uptake in lesions was compared with that in the corr

201 y demonstrated a 1.6-fold induction of (18)F-FDG uptake in murine atherosclerotic plaques by both M-C

202 AT, cold stress reduces blood flow and (18)F-FDG uptake in subcutaneous WAT, indicating that the phys

203 We assessed (18)F-FDG uptake in the arterial wall in 14 patients with CKD

204 y was to determine the relationship of (18)F-FDG uptake in the primary tumor at diagnosis, during the

205 etter characterize the determinants of (18)F-FDG uptake in various tumors and their surrounding micro

206 drenergic stimulation can increase BAT (18)F-FDG uptake independently of UCP1 thermogenic function.

207 hub between SDH-mutated tumors and the (18)F-FDG uptake profile.

208 mice demonstrated significantly lower (18)F-FDG uptake than WT mice in the thalamus (P = 0.0004) and

209 ntrol rats, while no focally increased (18)F-FDG uptake was detected in all ZDF-ND rats.

210 y published human data, in which fetal (18)F-FDG uptake was directly observed in vivo.

211 (18)F-FDG uptake was evaluated in murine atherosclerotic aorta

212 re diminished in UCP1 KO mice, but BAT (18)F-FDG uptake was fully retained.

213 (18)F-FDG uptake was not significantly increased from baseline

214 C, MM, GEP NET, and PCA correlated with(18)F-FDG uptake, (68)Ga-DOTATOC uptake, and (68)Ga-PSMA uptak

215 cause only active BAT is detectable by (18)F-FDG uptake, these numbers underestimate the total amount

216 ularly in the presence of low baseline (18)F-FDG uptake.

217 ified as having an abnormal pattern of (18)F-FDG uptake.

218 frequent management decision based on (18)F-FDG was initiation of chemotherapy (10 patients, 47.6%).

219 cumulates in apoptotic tumors in which (18)F-FDG was not able to differentiate responding from nonres

220 Positron lymphography using (18)F-FDG was successfully performed on tumor-bearing and non-

221 radio- and chemotherapy response with (18)F-FDG whole-body PET has attracted increasing interest in

222 (18)F-fluorodeoxyglucose ((18)F-FDG) PET/CT has demonstrated value for SPNs diagnosis wi

223 optimal use of (18)fluorodeoxyglucose ((18)F-FDG) PET/CT in patients with multiple myeloma and other

224 reflected by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (P

225 2'-[(18)F]-fluoro-2'-deoxy-D-glucose ((18)F-FDG).

226 More recently, PET/CT imaging with (18)F-FDG, (18)F-fluorodihydroxyphenylalanine (FDOPA), and (68

227 Although (18)F-FDG, (18)F-PBR111, and (18)F-AV45 all detected pathologi

228 through small-animal PET imaging with (18)F-FDG, (18)F-peripheral benzodiazepine receptor ((18)F-PBR

229 )F-FDOPA and (18)F-FDA are superior to (18)F-FDG, (68)Ga-DOTATATE, and CT/MRI and should be the radio

230 of a BRAF mutation was associated with (18)F-FDG-avid CNS disease (P = 0.0357), higher SUVmax (P = 0.

231 (18)F-FDG-avid lesions not only were found in impinged spinal

232 sociated with pTR, in 82 patients with (18)F-FDG-avid nodes before NAC we observed mNR in 10 (12.2%)

233 trongly recommend investigation of all (18)F-FDG-avid nodules 1 cm or larger with ultrasound and fine

234 val in a large cohort of patients with (18)F-FDG-avid TI with long-term follow-up to assess the valid

235 Although this study is an (18)F-FDG-based approach, it provides an impetus to better cha

236 However, no significant differences in (18)F-FDG-derived SUVs were observed between different grades

237 cantly higher fluorescence signal from (18)F-FDG-treated than untreated cells.

238 d approximately 1 h after injection of (18)F-FDG.

239 )F-FDS) can be easily synthesized from (18)F-FDG.

240 ent standard for breast PET imaging is (18)F-FDG.

241 ysfunction through the use of PET with (18)F-FDG.

242 s were acquired post-injection of free (18)F-FDG/(18)F-FLT or (18)F-FDG/(18)F-FLT-labelled HUVECs, fo

243 jection of free (18)F-FDG/(18)F-FLT or (18)F-FDG/(18)F-FLT-labelled HUVECs, following the surgical in

244 T in the gene, PPP4R3A, and reduced [(18) F] FDG decline (p = 4.44 x 10(-8) ).

245 emission tomography ([(18)F]FDG PET), [(18)F]FDG lacks cell specificity, and coronary imaging is unre

246 [(18)F]FDG mTBRmax differentiated culprit from nonculprit carot

247 -DOTATATE PET imaging was compared to [(18)F]FDG PET imaging in 42 patients with atherosclerosis.

248 glucose positron emission tomography ([(18)F]FDG PET), [(18)F]FDG lacks cell specificity, and coronar

249 for the first time, the detection of [(18)F]FDG radiotracer uptake in single cells through fluoresce

250 (18)F]FDG spillover rendered coronary [(18)F]FDG scans uninterpretable in 27 patients (64%).

251 0.91; p = 0.002); however, myocardial [(18)F]FDG spillover rendered coronary [(18)F]FDG scans uninter

252 95% CI: 0.32 to 0.69; p <0.0001) and [(18)F]FDG uptake (r = 0.73; 95% CI: 0.64 to 0.81; p < 0.0001).

253 Uptake of 2-[(18)F]FDG was greatest and continuously increasing owing to me

254 of hypometabolism (measured with PET [(18)F]FDG) or detectable fibrillary amyloidosis (measured with

255 6-deoxy-6-[(18)F]fluoro-d-glucose (6-[(18)F]FDG) was studied in EMT6 cells, tumors, and muscle and c

256 2-deoxy-2-[(18)F]fluoro-d-glucose (2-[(18)F]FDG), and 6-deoxy-6-[(18)F]fluoro-d-glucose (6-[(18)F]FD

257 ion by routine metabolic imaging with [(18)F]FDG-PET failed due to low standard uptake values and low

258 gnosing DLBCL in the clinic; however, [(18)F]FDG-PET often faces difficulty in differentiating malign

259 glucose positron emission tomography ([(18)F]FDG-PET) imaging has an essential role in diagnosing DLB

260 Use of [(18)F]FDG-positron emission tomography (PET) in clinical breas

261 versus low-risk coronary lesions than [(18)F]FDG.

262 as, and compared [(64)Cu]-LLP2A with [(18)F]-FDG over the course of infection.

263 ncrease in LN volume correlated with [(18)F]-FDG uptake and peaked 10 days postinfection, while minim

264 des of nonsurvivors showed increased [(18)F]-FDG uptake by day 4 postinfection with minimal lymph nod

265 Moribund NHPs demonstrated increased [(18)F]-FDG uptake in bone marrow 4 days postinfection compared

266 des of surviving monkeys, changes in [(18)F]-FDG uptake positively correlated with enlargement of the

267 g [(18)F]fluoro-2-deoxy-2-d-glucose ([(18)F]-FDG) is commonly used in PET/CT that is retained by meta

268 ional studies to demonstrate whether [(18)F]-FDG-PET/CT can identify other, subtler effects.

269 [(18)F]-FDG-PET/CT imaging can provide real-time snapshots of me

270 activity at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and survival in

271 accuracy of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with di

272 's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), and their assoc

273 ated fluorine 18 ((18)F) fluorodeoxyglucose (FDG) influx rates, tissue depots, and whole-body insulin

274 d by fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) and hyperpolariz

275 amic fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) has added value

276 und B (amyloid), and F18 fluorodeoxyglucose (FDG) in 90 clinically normal elderly of the Harvard Agin

277 CT) imaging with [(18)F]-fluorodeoxyglucose (FDG) can monitor monkeypox disease progression in vivo i

278 on breath hold (DIBH) in fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomogra

279 PET/CT) with 6.9 mCi of fluorodeoxyglucose (FDG) and magnetic resonance (MR) imaging of the upper ab

280 and to compare these to fluorodeoxyglucose (FDG) uptake and biologic markers of inflammation.

281 dal (n = 8) lesions and corresponded to foci FDG uptake, with mean SUVmax of 9.8, 6.7, and 16.2, resp

282 went DCE-MRI, and a subgroup of patients had FDG-PET.

283 eated group showed visible lesions, a higher FDG uptake and increasing enhancement.

284 tion is, therefore, needed when interpreting FDG PET/CT in suspected prosthetic valve endocarditis, w

285 iation to the FDG-avid tumor on midtreatment FDG-PET to improve local tumor control of locally advanc

286 MM patients with simultaneous assessment of FDG-PET and DWIBS, and to identify tumor-intrinsic featu

287 tory) may contribute to the inconsistency of FDG vessel wall inflammation.

288 e was the negative predictive value (NPV) of FDG-PET/CT scans and other supporting diagnostic test ch

289 performed a prospective multicenter study of FDG-PET/CT scanning 12 weeks after CCRT in newly diagnos

290 A periprosthetic FDG uptake was present in 47 (87%) and 30 (56%) PHVs wit

291 of temporoparietal FDG metabolism (mean [SD] FDG: Abeta-N+, 1.25 [0.11] vs Abeta+N+, 1.19 [0.11]), le

292 layed better preservation of temporoparietal FDG metabolism (mean [SD] FDG: Abeta-N+, 1.25 [0.11] vs

293 Adapting RT-escalated radiation dose to the FDG-avid tumor detected by midtreatment PET provided a f

294 ive RT can target high-dose radiation to the FDG-avid tumor on midtreatment FDG-PET to improve local

295 d from various texture features on dual time FDG PET/CT images (DTPI) can differentiate between malig

296 ron emission tomography/computed tomography (FDG-PET/CT) acquired during the course of treatment prov

297 ordeoxyglucose positron emission tomography (FDG-PET).

298 shape, texture) extracted from pre-treatment FDG-PET and CT images of 300 patients from four differen

299 n and temozolomide therapy and who underwent FDG PET/computed tomography because of radiologic deteri

300 monstrate a relevant number of patients with FDG-PET false-negative MM and a strong association betwe